Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. Traditionally, a bimodal distribution by age has been reported with peaks at the ages of 15 to 25 and between 36 to 46.
David Liew drdavidliew
1 year 5 months ago
Always great to have @EMA_News to come and to talk to us at #EULAR2023
Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍
@RheumNow https://t.co/hSutraUsFD
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 5 months ago
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Dr. John Cush RheumNow
1 year 5 months ago
NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5
Aurelie Najm AurelieRheumo
1 year 5 months ago
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC?
Brief answer is no, but:
-PsA > tortuous capillaries vs. PSO & HC
-Abnormalities in PSO to be used as predictor of PsA?
TBC...
@RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 5 months ago
#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT
Aurelie Najm AurelieRheumo
1 year 5 months ago
Fluorescence optical imaging in early arthritis?
Nice images but not ready for clinics yet
Can not differentiate OA from RA & PsA
SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis
OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Dr. John Cush RheumNow
1 year 5 months ago
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023
Dr. John Cush RheumNow
1 year 5 months ago
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush RheumNow
1 year 5 months ago
Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh
Aurelie Najm AurelieRheumo
1 year 5 months ago
🛑Doing Hands and feet Xray in undifferentiated arthritis?
Retro study 700+pts shows:
✔️only few patients w/ UA present w/ RA-associated erosions at presentation
✔️Rarely leads to change in diagnosis or prognosis.
Will you stop? I probably won't 👀
@RheumNow #EULAR23 OP0172 https://t.co/BRpmDqaN0r
Janet Pope Janetbirdope
1 year 5 months ago
#Lupus #nephritis - many trials and this is one company #Roche and other #pharmaceutical CO’s are also involved #Hope #SLE #EULAR2023 @RheumNow @eular_org https://t.co/Giu2iUqq6j
David Liew drdavidliew
1 year 5 months ago
The steroid dosing in SAPHYR (sarilumab in PMR):
Bottom two trajectories: sarilumab protocol & actual
Top two trajectories: placebo protocol & actual
Fascinating that with sarilumab, more PNL only really in play at PNL <3mg/d. Def takes the heat out
POS0715 #EULAR2023 @RheumNow https://t.co/aEC8cQaR7O
Dr. John Cush RheumNow
1 year 5 months ago
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
Dr. Antoni Chan synovialjoints
1 year 5 months ago
• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH)
• Bone pain, xanthelasma, hairy kidney
• Differential diagnoses of LCH
• BRAF mutation associated with cardiac and neurological phenotype of ECD
Haroche J, Papo M
#EULAR2023
@RheumNow https://t.co/AzKJKp82nq